Estrogen receptor polymorphisms and the vascular effects of hormone therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 2, 2011, Pages 464-469

  Rossouw, Jacques ^a   Bray, Paul ^b   Liu, Jingmin ^c   Kooperberg, Charles ^d   Hsia, Judith ^e   Lewis, Cora ^f   Cushman, Mary ^g   Bonds, Denise ^a   Hendrix, Susan ^h   Papanicolaou, George ^a   Howard, Timothy ⁱ   Herrington, David ^j  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Fred Hutchinson Public Health Sciences Division   (United States)

^d Fred Hutchison Cancer Research Center   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h DETROIT MEDICAL CENTER   (United States)

ⁱ Center for Genomics and Pesonalized Medicine Research   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

blood coagulation; clinical trials; coronary artery disease; epidemiology; estrogen; pulmonary embolism; receptors; stroke

Indexed keywords

ANTIPLASMIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PLASMIN;

ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; GENOTYPE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RISK FACTORS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 79551497025     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.215087     Document Type: Article

References (35)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
2. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen J, Curb JD, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; Women's Health Initiative Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003; 289:2673-2684.
3. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
4. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292: 1573-1580.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291: 1701-1712.
6. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006; 113:2425-2434. (Pubitemid 43948050)
7. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357-365. (Pubitemid 43244325)
8. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-780.
9. Bray PF, Larson JC, LaCroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL; Women's Health Initiative Investigators. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol. 2008; 101:1599-1605.
10. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger MS, Robinson J, Hendrix S, Hsia J. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med. 2008;168:2245-2253.
11. Hsia J, Otvos JD, Rossouw JE, Wu L, Wassertheil-Smoller S, Hendrix SL, Robinson JG, Lund B, Kuller LH; for the Women's Health Initiative Research Group. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative Hormone Trials. Arterioscler Thromb Vasc Biol. 2008;28:1666-1671.
12. Kooperberg C, Cushman M, Hsia J, Robinson JG, Aragaki AK, Lynch JK, Baird AE, Johnson KC, Kuller LH, Beresford SAA, Rodriguez B. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials. 2007;2:e28.
13. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor poly-mophisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
14. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879-1882.
15. De Maat MPM, Madsen JS, Langdahl B, Bladberg EM, Tofteng CL, Abramsen B, Rejnmark L, Brixen K, Chrisenen K, Jespersen J, Kristensen SR. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thromb Haemostasis. 2007;97:234-239.
16. Lehtimaki T, Kunnas TA, Mattila KM, Perola M, Penttila A, Koivula T. Coronary wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med. 2002;80:176-180.
17. Rokach A, Pollak A, Rosen L, Friedlander Y, Blumenfeld A, Reznik L, Dresner-Pollak R. Estrogen receptor a gene polymorphisms are associated with the angiographic extent of coronary artery disease. J Clin Endocrinol Metab. 2005;90:6556-6560.
18. Alevizaki M, Saltiki K, Cimponeriu A, Kanakakis I, Xita N, Alevizaki CC, Georgiou I, Sarika H-L. Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor a polymorphic variants. Eur J Endocrinol. 2007;156:489-496.
19. Shearman AM, Cooper JA, Kotwinski PJ, Humphries SE, Mendelsohn ME, Housman DE, Miller GJ. Estrogen receptor a gene variation and the risk of stroke. Stroke. 2005;36:2281-2282.
20. Shearman AM, Demissie S, Cupples LA, Peter I, Schmid CH, Ordovas JM, Mendelsohn ME, Housman DE. Tobacco smoking, estrogen receptor a gene variation and low density lipoprotein cholesterol. Hum Mol Genet. 2005;14:2405-2413.
21. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG. Estrogen receptor a gene polymorphisms and risk of myocardial infarction. JAMA. 2004;291:2969-2977.
22. Klos KLE, Boerwinkle E, Ferrell RE, Turner ST, Morrison AC. ESR1 polymorphism is associated with plasma lipid and apoprotein levels in Caucasians of the Rochester Family Heart Study. J Lipid Res. 2008;49: 1701-1706.
23. Koch W, Hoppmann P, Pfeufer A, Meuller JC, Schomig A, Kastrati A. No replication of association between estrogen receptor a gene polymorphisms and susceptibility to myocardial infarction in a large sample of patients of European descent. Circulation. 2005;112:2138-2142.
24. Lawlor DA, Timpson N, Ebrahim S, Day INM, Smith GD. The association of oestrogen receptor a-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study. Eur Heart J. 2006;27:1597-1604. (Pubitemid 43954920)
25. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Grønholdt ML, Grande P, Jensen GB, Nordestgaard BG. Estrogen receptor a gene polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation. 2007;115:861-871.
26. Bos MJ, Schuit SCE, Koudstaal PJ, Hofman A, Uitterlinden AG, Breteler MMB. Variation in estrogen receptor a gene and risk of stroke: the Rotterdam Study. Stroke. 2008;39:1324-1326.
27. Christian RC, Liu PY, Harrington S, Ruan M, Miller VM, Fitzpatrick LA. Intimal estrogen receptor (ER) /3, but not ERa expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J Clin Endocrinol Metab. 2006;91:2713-2720.
28. Rexrode KM, Ridker PM, Hegener HH, Buring JE, Manson JE, Zee RYL. Polymorphisms and haplotypes of the estrogen receptor /3 gene (ESR-2) and cardiovascular disease in men and women. Clin Chem. 2007;53: 1749-1756.
29. Straczek C, Alhenc-Gelas M, Aubry ML, Scarabin P-Y; on behalf of the Estrogen and Thromboembolism Risk (ESTHER) Study Group. Genetic variation at the estrogen receptor a locus in relation to venous thromboembolism risk among postmenopausal women. J Thromb Haemost. 2005; 3:1535-1537.
30. Oger E, Lacut K, Mercier B, Le Gal G, Leroyer C, Pasquier E, Ferec C, Mottier D. Estrogen receptor a polymorphism and venous thromboembolism in male and female: data from the EDITH study. Thromb Res. 2007;119:433-439.
31. Devlin P, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 1995;29:311-322.
32. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. CRC Monograph on Statistics and Applied Probability. New York, NY: Chapman and Hall; 1993; series 57.
33. Westfall PH, Young SS. Resampling-Based Multiple Testing. New York, NY: John Wiley & Sons; 1993.
34. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-a-2-antiplasmin complex in human plasma: application to the detection of in vivo activation of the fibrolytic system. Thromb Haemost. 1986;56: 124-127.
35. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, Tracy RP. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999;149:261-267.